NCT03448835View on ClinicalTrials.gov

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 7, 2018

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Stomach CancerGastro Esophageal Junction Cancer
Interventions
DRUG

Atezolizumab

atezolizumab 1200 mg 5 cycles

DRUG

Capecitabine

capecitabine 850 mg /m2 4 cycles

DRUG

Oxaliplatin

oxaliplatin 100 mg/m2 4 cycles

DRUG

Docetaxel

docetaxel 50 mg/m2 4 cycles

Trial Locations (2)

1066CX

Marieke van de Belt, Amsterdam

Unknown

Catharina ziekenhuis, Eindhoven

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03448835 - Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) | Biotech Hunter | Biotech Hunter